Patent details

LUC50004 Product Name: daratumumab, bortezomib, lenalidomide and dexamethasone

Basic Information

Publication number:
LUC50004
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP078178167
Legal Status:
Pending & Published
Application number:
LUC50004
First applicant's nationality:
Procedural language:
English

Marketing Authorization

Marketing Authorization Number:
EU/1/16/1101
Marketing Authorization Type:
Marketing Authorization Date:
21/10/2024
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
15/04/2025
First Marketing Authorization date:
21/10/2024
Grant date:
Activation date:
Publication date:
18/04/2025
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
26/09/2032
SPC Extension Expiration:
26/09/2032
Rejection date:
Withdrawal date:

Owner

From:
15/04/2025
 
 

Name:
GENMAB A/S
Address:
Carl Jacobsens Vej 30, DK-2500, Valby, Denmark (DK)

Agent

Name:
Dennemeyer & Associates S.A.
From:
15/04/2025
Address:
55, rue des Bruyères, L-1274, HOWALD, Luxembourg (LU)
To:

Publication

Bulletin

Bulletin Heading:
SPC1
Bulletin edition number:
2025/06
Publication date:
12/05/2025
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

Annual Fees

Annual Fee Due Date:
30/09/2027
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
18/04/2025 Outgoing Correspondence 1
18/04/2025 Publication 1
15/04/2025 Application Form 4
15/04/2025 General Document 1
15/04/2025 Outgoing Correspondence 2
15/04/2025 General Document 106
15/04/2025 General Document 8
15/04/2025 General Document 5
15/04/2025 General Document 3
15/04/2025 General Document 1
15/04/2025 Outgoing Correspondence 2
15/04/2025 General Document 1
15/04/2025 General Document 1
15/04/2025 Incoming Correspondence (Email) 2